Back
Corporate News
HSIL acquires majority stake in Lifesenz Cancer Research Labs
10-Jun-2026, 11:21
Hemant Surgical Industries has completed the strategic acquisition of a majority stake (66.66%) in Lifesenz Cancer Research Labs (Lifesenz), a company focused on precision oncology and personalized cancer treatment solutions for an amount of Rs. 19.98 crore, making Lifesenz a subsidiary of the Company with effect from 01 June 2026.
Hemant Surgical Industries has completed the strategic acquisition of a majority stake (66.66%) in Lifesenz Cancer Research Labs (Lifesenz), a company focused on precision oncology and personalized cancer treatment solutions for an amount of Rs. 19.98 crore, making Lifesenz a subsidiary of the Company with effect from 01 June 2026.